Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of cervical carcinoma tumor-infiltrating lymphocyte outgrowth
NL-OMON53901Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2023
- Modality
- Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of GC101 TIL + pembrolizumab in Cervical Cancer (CC), sponsored by Netherlands Cancer Institute. Primary endpoints: Collection of malignant tissue, Establishment of TIL culture protocol and 1 more. Started Jun 2023; status: completed.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON53901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53901.